Metropolis Q2FY26 Growth Highlights

  Published 7 months ago

Metropolis Healthcare posted strong Q2FY26 growth across diagnostics, wellness, B2C, and B2B segments with profitability.

  • Core Diagnostics, Scientific Pathology, Agra, DAPIC, and TruHealth drove 25‑36% YoY segment growth across segments.
  • B2C revenues rose 16% YoY; B2B surged 34% thanks to core diagnostics expansion in 2025.
  • Acquired Ambika Pathology, adding Kolhapur presence; the company remains debt‑free with Rs 55 crore cash and growth.

You might like these

Endurance Tech Q1 FY26 Results Snapshot

Virtuoso Begins Compressor Production

Regaal Resources IPO Surges on Debut

Aadhaar Transactions Surge in June 2025

CMS Info Systems Rebrands

EV Sales Surge in India: 7.7% Market Share

Paytm Stock Rises on Tax Relief

News that matters the most ⚡